Evidence map›Paper›PMID 38483616›Full record

ArticleJournal of cancer research and clinical oncology2024

GATA6 inhibits the biological function of non-small cell lung cancer by modulating glucose metabolism.

Weiwei Ju, Lijuan Lin, Qifang Zhang, Xiumei Lv, Shaohui Teng, Yu Hong, Zhixiang Shao, Hanyun Na, Shengjin Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Weiwei JuInstitute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.
Lijuan LinInstitute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.
Qifang ZhangInstitute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.
Xiumei LvInstitute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.
Shaohui TengInstitute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.
Yu HongInstitute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China.
Zhixiang ShaoPathology Department, Dandong First Hospital, Dandong, 118003, China.
Hanyun NaPathology Department, Dandong First Hospital, Dandong, 118003, China.
Shengjin YuInstitute of Molecular Medicine, Medical College of Liaodong University, Dandong, 118003, China. yubing557@163.com.
Eastern Liaoning University · CNPudong Medical Center · CN

Funding

Education Department in Liaoning Province LJKMZ20221762Joint Fund Program Project of Liaodong University Research Fund 2022YB004
6 · The paper itself

Abstract

purposeThis study aims to explore the role of GATA6 in lung cancer, with a focus on its impact on metabolic processes.

methodsWe assessed GATA6 expression in lung cancer tissues and its association with patient prognosis. In vitro cell function experiments were conducted to investigate the effects of altered GATA6 levels on lung cancer cell proliferation and migration. Mechanistic insights were gained by examining GATA6's influence on glucose metabolism-related genes, particularly its effect on c-Myc mRNA expression.

resultsOur study revealed significant down-regulation of GATA6 in lung cancer tissues, and this down-regulation was strongly correlated with unfavorable patient prognosis. Elevating GATA6 levels effectively inhibited the proliferation and migration of lung cancer cells in our cell function experiments. Mechanistically, we found that GATA6 suppressed the expression of c-Myc mRNA, impacting genes related to glucose metabolism. As a result, glucose uptake and metabolism in lung cancer cells were disrupted, ultimately impeding their malignant behaviors.

conclusionOur study provides crucial insights into the metabolic regulation of GATA6 in lung cancer cells. These findings have the potential to offer a solid theoretical foundation for the development of novel clinical treatments for lung cancer.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell Line, TumorCell ProliferationGATA6 Transcription FactorGene Expression Regulation, NeoplasticGlucoseHumansRNA, MessengerGATA6 protein, humanGATA6 Transcription FactorGlucoseRNA, Messengerc-MycGATA6Glucose metabolismNon-small cell lung cancer

Identifiers

PMID38483616
PMCPMC10940364
OpenAlexW4392805604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.